Description
Azithromycin (500 mg for 5 days) demonstrated significant clinical improvement in URTIs with minimal adverse events, making it a safe and effective option for real-world management, in a new study. Sore throat cases dropped from 95.8% to 10.4%, and fever resolved in 97.4%. Work absenteeism decreased significantly from 47.9% to 1% after treatment.